15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Arcturus Therapeutics Holdings Inc, 7 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $9.00 to $54.00 (about 6.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $25.13 sits 337% above the current $5.75. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees revenue growth near -53% this year and 10% next, consensus EPS building from about $-0.88 next quarter toward $-4.02 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy778%
Hold222%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Arcturus Therapeutics Holdings Inc.
As of Jul, 7 of 9 firms rate ARCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.88
Range $-1.42 – $0.37 · 11 analysts · +79% YoY
Next period, 11 analysts expect Arcturus Therapeutics Holdings Inc to earn $-0.88 a share (range $-1.42 – $0.37), versus $-0.49 a year earlier. Full-year consensus is $-3.86, growing to $-4.02 the year after.
REVENUE · NEXT QUARTER
$7.5M
Range $1.8M – $48.2M · 11 analysts · -61% YoY
Revenue is expected to reach $7.5M (range $1.8M – $48.2M), -61.0% year-over-year. Full-year consensus is $22.0M, rising to $33.0M next year.
Top analysts covering Arcturus Therapeutics Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARCT.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$22.00+282.6% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #35
Hold
$9.00+56.5% to target
Overall win rate
46%
+ Follow
#3
Ed Arce
HC Wainwright & Co. · Rank #107
Buy
$60.00+943.5% to target
Overall win rate
44%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #131
Hold
$8.00+39.1% to target
Overall win rate
43%
+ Follow
#5
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
No targeton ARCT
Overall win rate
38%
+ Follow
ARCT stock forecast FAQ
What is ARCT's average 12-month price target?+
The 8 analysts with a live target average $25.13 for Arcturus Therapeutics Holdings Inc over the next 12 months, ranging from a $54.00 high to a $9.00 low.
Is ARCT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 7 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ARCT?+
The Street-high target is $54.00 (Leerink Partners), and the Street-low is $9.00 (HC Wainwright & Co.). The average of all 8 active targets is $25.13.
How many Wall Street analysts cover ARCT?+
9 analysts have an active rating on Arcturus Therapeutics Holdings Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering ARCT?+
Among analysts who currently cover ARCT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $22.00 target.
What is Arcturus Therapeutics Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $-0.88 per share (range $-1.42 – $0.37) across 11 analysts. Full-year EPS is projected at $-3.86, rising to $-4.02 the following year.
How much revenue is Arcturus Therapeutics Holdings Inc expected to report next quarter?+
Consensus revenue is $7.5M (range $1.8M – $48.2M). Full-year revenue is projected at $22.0M, growing to $33.0M next year.
Have analysts been upgrading or downgrading ARCT lately?+
As of Jul, 7 of 9 firms rate ARCT a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
